Episode Details

Back to Episodes
BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

Published 1 year, 2 months ago
Description

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us